Treatment against Covid: The World Health Organization has announced the launch of an international trial of three drugs to find out if they improve the condition of hospitalized Kovid patients. Artesunate (artesunate), imatinib (imatinib) and infliximab (infliximab) will be tested in volunteer patients in more than 600 hospitals in 52 countries.
On August 11, Tedros Adhanom Ghebreyesus, the head of the health agency, said: “The need of the hour is to find a more effective and accessible treatment for patients with Kovid-19. Artesunate is used to treat severe malaria, imatinib is used to prevent certain types of cancer, and infliximab is used to treat diseases of the immune system such as joint pain and Crohn’s disease.
WHO’s big announcement under “shared tests”
The World Health Organization says joint research in dozens of countries will allow trials to reach multiple treatments while remaining within a protocol, while estimating the effect of each drug on patients. Given the ability to reduce the risk of death in hospital-treated Covid-19 patients, the drugs for the trial were selected by an independent panel. The manufacturers donated the drugs and have already been delivered to hospitals participating in the trial.
The three-drug investigation in Covid-19 patients is part of the second phase of the organization’s campaign to find an effective treatment for the corona virus. Previously, in the first phase of the “joint trial”, the effect of four drugs was evaluated in 13,000 patients in 500 hospitals in 30 countries. Preliminary results published in October 2020 showed that remdesivir, hydroxylaraquine, lopinavir and interferon were not benefiting COVID-19 patients treated in hospitals (Treatment against Covid).
A trial of 3 drugs will be done against Covid
The results of the first phase of the trials are expected to be published in September next month. The organization’s advisory group recommended an evaluation because of its anti-inflammatory properties, which have been used for over 30 years in the treatment of malaria and other parasitic diseases and considered very safe. Human trials with imatinib in the Netherlands have shown that it may benefit hospital patients with Covid. Likewise, infliximab is known to be safe and effective in preventing inflammation. In Covid-19 patients, the risk of complications increases with increasing intensity of inflammation.
